Factors Affecting Plasma Lipoprotein(a) Levels: Role of Hormones and Other Nongenetic Factors

Lp(a) appears to be one of the most atherogenic lipoproteins. It consists of an low-density lipoprotein core in addition to a covalently bound glycoprotein, apo(a). Apo(a) exists in numerous polymorphic forms. The size of the polymorphism is mediated by the variable number of kringle-4 Type 2 repeats found in apo(a). Plasma Lp(a) levels are determined to more than 90% by genetic factors. Plasma Lp(a) levels in healthy individuals correlate significantly highly with apo(a) biosynthesis, and not with its catabolism. There are several hormones that are known to have a strong effect on Lp(a) metabolism. In certain diseases, such as kidney disease, the Lp(a) catabolism is impaired, leading to elevations that are up to a fivefold increase. Lp(a) levels rise with age but are otherwise only little influenced by diet and lifestyle. There is no safe and efficient way of treating individuals with elevated plasma Lp(a) concentrations. Most of the lipid-lowering drugs have either no significant influence on Lp(a) or exhibit a variable effect in patients with different forms of primary and secondary hyperlipoproteinemia.

KEYWORDS

Hormones - plasma lipoprotein (a) levels

REFERENCES

• 1 Berg K. A new serum type system in man: the Lp system.  Acta Pathol Microbiol Scand. 1963;  59 369-382
• 2 Marcovina S M, Koschinsky M L, Albers J J, Skarlatos S. Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: recent advances and future directions.  Clin Chem. 2003;  49 1785-1796
• 3 McLean J W, Tomlinson J E, Kuang W J et al.. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen.  Nature. 1987;  330 132-137
• 4 Gries A, Nimpf J, Nimpf M, Wurm H, Kostner G M. Free and apoB-associated Lp(a) specific protein in human serum.  Clin Chim Acta. 1987;  164 93-100
• 5 Utermann G, Menzel H J, Kraft H G, Duba H C, Kemmler H G, Seitz C. Lp(a) glycoprotein phenotypes: inheritance and relation to Lp(a)- lipoprotein concentrations in plasma.  J Clin Invest. 1987;  80(2) 458-465
• 6 White A L, Lanford R E. Cell surface assembly of lipoprotein(a) in primary cultures of baboon hepatocytes.  J Biol Chem. 1994;  269 28716-28723
• 7 Catena C, Novello M, Dotto L, De Marchi S, Sechi L A. Serum lipoprotein(a) concentrations and alcohol consumption in hypertension: possible relevance for cardiovascular damage.  J Hypertens. 2003;  21 281-288
• 8 Wright L C, Sullivan D R, Muller M, Dyne M, Tattersall M H, Mounford C E. Elevated apolipoprotein(a) levels in cancer patients.  Int J Cancer. 1989;  43 241-244
• 9 Syrovets T, Thillet J, Chapman J, Simmet T. Lp(a) is a potent chemoattractant for human peripheral monocytes.  Blood. 1997;  90(5) 2027-2036
• 10 Ko S H, Song K H, Ahn Y B et al.. The effect of rosiglitazone on serum lipoprotein(a) levels in Korean patients with type 2 diabetes mellitus.  Metabolism. 2003;  52(6) 731-734
• 11 Clodi M, Oberbauer R, Waldhäusl W, Maurer G, Kostner G M, Kostner K. Urinary excretion of apo(a) fragments in NIDDM patients.  Diabetologia. 1997;  40 1455-1460
• 12 Laron Z, Klinger B, Silbergeld A, Wang X L. Opposing effects of growth hormone and insulin-like growth factor I on serum lipoprotein(a).  J Pediatr Endocrinol Metab. 1997;  10 143-149